MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, ALURW had -$9,976K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$9,976K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from public offerings, ...
    • Change in fair value of revenue ...
    • Proceeds from private offerings,...
    • Others
Negative Cash Flow Breakdown
    • General and administrative
    • Change in fair value of warrant ...
    • Sales and marketing
    • Others

Cash Flow
2025-12-31
Revenue
15,230
Cost of revenue
5,659
Sales and marketing
10,804
Research and development-Clinical Trials And Medical Affairs
3,020
Research and development-Product Development
1,848
Research and development-Digital
969
Research and development-Quality And Regulatory
1,733
General and administrative
21,353
Other segment items
1,401
Net loss
-28,755
Non-cash lease expense
679
Depreciation and amortization
983
Stock-based compensation
3,146
Provision for uncollectible accounts
2,847
Unrealized exchange gain (loss) and other
206
Provision for inventory
1,216
Change in fair value of warrant liabilities
-12,800
Change in fair value of debt
3,615
Change in fair value of revenue interest financing and pipe conversion option
-9,090
Change in fair value of earn-out liabilities
1,059
Change in fair value of rtw share obligation
370
Interest paid on debt recorded at fair value
2,410
Loss on extinguishment of debt
-660
Issuance costs associated with warrants recorded at fair value
1,502
Accounts receivable
-844
Inventory
486
Prepaid expenses, other current and long-term assets
-800
Lease liabilities
-796
Accounts payable
-3,141
Accrued expenses and other current liabilities
-5,045
Net cash used in operating activities
-28,946
Proceeds from private offerings, net of issuance costs
4,597
Proceeds from public offerings, net of issuance costs
13,578
Proceeds from equity line financing
795
Net cash provided by financing activities
18,970
Net decrease in cash and cash equivalents and restricted cash
-9,976
Cash and cash equivalents and restricted cash at beginning of period
15,718
Cash and cash equivalents and restricted cash at end of period
5,742
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from publicofferings, net of issuance...$13,578K Proceeds from privateofferings, net of issuance...$4,597K Proceeds from equity linefinancing$795K Net cash provided byfinancing activities$18,970K Net decrease in cashand cash...-$9,976K Canceled cashflow$18,970K Change in fair value ofrevenue interest...-$9,090K Change in fair value ofdebt$3,615K Stock-based compensation$3,146K Provision foruncollectible accounts$2,847K Issuance costsassociated with warrants...$1,502K Provision for inventory$1,216K Depreciation andamortization$983K Accounts receivable-$844K Prepaid expenses, othercurrent and long-term...-$800K Non-cash lease expense$679K Loss onextinguishment of debt-$660K Change in fair value ofrtw share...$370K Net cash used inoperating activities-$28,946K Canceled cashflow$25,752K Revenue$15,230K Other segment items$1,401K Net loss-$28,755K Change in fair value ofwarrant liabilities-$12,800K Canceled cashflow$16,631K Accrued expenses andother current...-$5,045K Accounts payable-$3,141K Interest paid on debtrecorded at fair value$2,410K Change in fair value ofearn-out liabilities$1,059K Lease liabilities-$796K Inventory$486K Unrealized exchange gain(loss) and other$206K General andadministrative$21,353K Sales and marketing$10,804K Cost of revenue$5,659K Research anddevelopment-Clinical Trials And...$3,020K Research anddevelopment-Product Development$1,848K Research anddevelopment-Quality And Regulatory$1,733K Research anddevelopment-Digital$969K

ALLURION TECHNOLOGIES, INC. (ALURW)

ALLURION TECHNOLOGIES, INC. (ALURW)